Progression-free survival was significantly longer in the pazopanib plus paclitaxel group than in the paclitaxel only group ( median @ months -LSB- @ % CI @-@ -RSB- vs @ months -LSB- @-@ -RSB- ; hazard ratio @ -LSB- @ % CI @-@ -RSB- ; p = @ ) .